- Home
- ATOS vs ACHV Comparison
ATOS vs ACHV Comparison
Compare ATOS & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- ACHV
- Stock Information
- Founded
- ATOS 2009
- ACHV N/A
- Country
- ATOS United States
- ACHV Canada
- Employees
- ATOS N/A
- ACHV N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATOS Health Care
- ACHV Health Care
- Exchange
- ATOS Nasdaq
- ACHV Nasdaq
- Market Cap
- ATOS 114.5M
- ACHV 126.9M
- IPO Year
- ATOS 2012
- ACHV N/A
- Fundamental
- Price
- ATOS $0.80
- ACHV $3.17
- Analyst Decision
- ATOS Strong Buy
- ACHV Strong Buy
- Analyst Count
- ATOS 3
- ACHV 5
- Target Price
- ATOS $7.00
- ACHV $14.80
- AVG Volume (30 Days)
- ATOS 678.1K
- ACHV 229.0K
- Earning Date
- ATOS 03-31-2025
- ACHV 03-27-2025
- Dividend Yield
- ATOS N/A
- ACHV N/A
- EPS Growth
- ATOS N/A
- ACHV N/A
- EPS
- ATOS N/A
- ACHV N/A
- Revenue
- ATOS N/A
- ACHV N/A
- Revenue This Year
- ATOS N/A
- ACHV N/A
- Revenue Next Year
- ATOS N/A
- ACHV N/A
- P/E Ratio
- ATOS N/A
- ACHV N/A
- Revenue Growth
- ATOS N/A
- ACHV N/A
- 52 Week Low
- ATOS $0.72
- ACHV $2.84
- 52 Week High
- ATOS $2.31
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- ATOS 41.00
- ACHV 44.06
- Support Level
- ATOS $0.79
- ACHV $3.18
- Resistance Level
- ATOS $0.89
- ACHV $3.59
- Average True Range (ATR)
- ATOS 0.05
- ACHV 0.21
- MACD
- ATOS 0.01
- ACHV 0.01
- Stochastic Oscillator
- ATOS 25.14
- ACHV 19.48
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.